The company said Tuesday that the trial met its primary endpoint of overall survival, showing a statistically significant and clinically meaningful improvement. The study tested galinpepimut-S, also known as GPS, as maintenance therapy in patients who had reached a second or later complete remission—or complete remission with insufficient platelet recovery—after second- or later-line salvage therapy and could not undergo allogeneic stem cell transplantation.
GPS was generally well tolerated, Sellas said, with a safety profile consistent with earlier trials. Treatment-related adverse events were predominantly mild to moderate.
Sellas plans to meet with the Food and Drug Administration to discuss the results and the possibility of seeking an accelerated application for the drug. The company also said it would advance preparations for a Biologics License Application submission in the first half of 2027.
“Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible,” Chief Executive Angelos Stergiou said.





Comments (0)
No comments yet. Be the first!